HomeOpen Access NewsPharmaceutical Industry

Pharmaceutical Industry

Tackling AMR and medicine shortages in the EU

How can the EU’s pharmaceutical legislation help tackle current challenges, including medicine shortages and antimicrobial resistance, across Europe? We put the question to Rainer Becker, Director for Medical Products and Innovation at DG SANTE.

Ilesol Pharmaceuticals: First European cannabinoid à la carte company

Here, Ilesol Pharmaceuticals discuss how they became the first European cannabinoid company to unlock this sector of the market.

CBD: Narcotic substance or a novel food product?

CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.

Stop drug testing and start impairment testing

A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.

EUMCA: Limit of 0.2% THC in CBD products should not change

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.

How are different types of medical cannabis working for different diseases?

Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.

How cannabinoids can be used as pain medicine

Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.

The EUMCA: Pioneering access to medicinal cannabis

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.

Expanding the portfolio of rigorous cannabinoid research with new funding opportunities

David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.

How does research in biochemistry fit into the wider goals of the NIH?

Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.

Cytochromes P450: Chemistry for drugs, metabolism, and beyond

Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.

The export of medicinal cannabis from Israel

Kathleen Denoodt shares with us what we need to know about the export of medicinal cannabis from Israel.

Gyrase and topoisomerase IV: Repurposing old targets for new antibacterials

Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.

A vision on remote decentralised clinical trials

Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.

Oncology: Imaging biomarkers and the Alberta Radiopharmaceutical Collaboration

Dr Frank Wuest, Professor at Department of Oncology - University of Alberta, sheds light on the imaging biomarkers and the Alberta Radiopharmaceutical Collaboration in this special oncology focus.

Enduring research: The constant threat of influenza virus outbreaks

Here, experts Stephan Pleschka, Oliver Planz and Stephan Ludwig walk us through the constant threat of influenza virus outbreaks and the benefit of enduring research in antiviral drug development.

Can cannabidiol (CBD) treat epilepsy?

Here, OilsBySimpson Founder Kevin William Simpson, explains what current research shows about CBD’s effect on epilepsy and its applications as a treatment.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders